Pyxis Oncology prices unregistered private placement at USD 50 million

• Pyxis Oncology priced an unregistered private placement for about USD 50 million in gross proceeds, with up to USD 64 million more from warrant exercises.
• Sale covers 19,600,153 common shares at USD 2.55 each, paired with warrants for the same number of shares.
• Warrants carry a USD 3.29 exercise price, with exercise permitted under the terms including cashless exercise.
• Proceeds forecast to extend cash runway into Q2 2027, supporting MICVO clinical follow-up in recurrent or metastatic head and neck cancer.
• Transaction expected to close around July 2, 2026, subject to customary conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pyxis Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-294613), on July 02, 2026, and is solely responsible for the information contained therein.